Market Overview

UPDATE: Oppenheimer Downgrades Chemtura to Perform on Limited Upside to Margin Improvement

Related CHMT
Chemtura Names Simon Medley Executive VP, Industrial Performance Products And Great Lakes Solutions
Benzinga's Top Downgrades

Oppenheimer downgraded Chemtura (NYSE: CHMT) from Outperform to Perform and removed the price target of $24.00.

Oppenheimer noted, "CHMT continues to take significant strides structurally upgrading its business, the reason for our original Outperform, but things have changed to warrant a downgrade to Perform: 1) 2012 EPS growth of 29% was despite volume down 1%, and 4Q12 results showed that the company may be approaching the limits to further margin improvement without a healthier economy, thus we pare back estimates for 2013; 2) stock comp expense was previously understated, and 4Q saw a large $6M catch-up; 3) legacy overhead costs from the antioxidants sale will hamper margin; 4) mix deteriorated in petroleum additives; 5) 2013 capex needs are higher than expected; and 6) the stock was up 87% last year (vs. 13% for the S&P 500) and 3% YTD (vs. 4%)."

Chemtura closed at $21.96 on Monday.

Latest Ratings for CHMT

DateFirmActionFromTo
Sep 2014KeyBancDowngradesBuyHold
Jul 2013Piper JaffrayMaintainsOverweight
Jun 2013OppenheimerDowngradesMarket PerformUnderperform

View More Analyst Ratings for CHMT
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Analyst Ratings

 

Related Articles (CHMT)

Around the Web, We're Loving...

Get Benzinga's Newsletters